Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 16/20 | 0.60 |
| ▸ | ESR2 | Q92731 | 13/20 | 0.60 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6438989 | 1.00 | ESR1 (0.60) | ESR1ESR2CYP26A1BACE1CA12 | |
| SCHEMBL7623056 | 0.95 | ESR2 (0.61) | ESR1ESR2CYP26A1CA12AKR1B10 | |
| SCHEMBL7632234 | 0.95 | ESR2 (0.61) | ESR1ESR2CYP26A1CA12AKR1B10 | |
| SCHEMBL5125832 | 0.93 | ESR1 (0.62) | ESR1ESR2CYP26A1BACE1 | |
| SCHEMBL5125836 | 0.93 | ESR1 (0.62) | ESR1ESR2CYP26A1BACE1 | |
| SCHEMBL7626609 | 0.91 | ESR1 (0.65) | ESR1ESR2 | |
| SCHEMBL7629536 | 0.91 | ESR1 (0.65) | ESR1ESR2 | |
| SCHEMBL5124945 | 0.88 | ESR1 (0.59) | ESR1ESR2CA12AKR1B10CA1 | |
| SCHEMBL5124941 | 0.88 | ESR1 (0.59) | ESR1ESR2CA12AKR1B10CA1 | |
| SCHEMBL5116896 | 0.87 | ESR1 (0.54) | ESR1ESR2CYP26A1BACE1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105148-A1 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-05 | — | — | US | claimed |
| EP-0955286-B1 | Dihydro- or tetrahydronaphthalene derivatives having (anti-)estrogen activity | AVENTIS PHARMA SA (FR) | 2002-08-07 | — | — | EP | claimed |
| US-6927224-B2 | Selective estrogen receptor modulators | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-09 | — | — | US | disclosed |
| US-20030105148-A1 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-05 | — | — | US | disclosed |
| EP-0955286-B1 | Dihydro- or tetrahydronaphthalene derivatives having (anti-)estrogen activity | AVENTIS PHARMA SA (FR) | 2002-08-07 | — | — | EP | disclosed |
| US-6005003-A | OSTEOPOROSIS TREATMENT | HOECHST MARION ROUSSEL (FR) | 1999-12-21 | — | — | US | disclosed |
| EP-0955286-A1 | Dihydro- or tetrahydronaphthalene derivatives having (anti-)estrogen activity | HOECHST MARION ROUSSEL (FR) | 1999-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105148-A1 | Selective estrogen receptor modulators | ESR1, GPER1, PTGIR | ESR1 1/4885ESR2 8/4885CYP26A1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.